<DOC>
	<DOCNO>NCT00003379</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Paclitaxel cisplatin may increase effectiveness radiation therapy make tumor cell sensitive radiation . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness radiation therapy pelvis plus paclitaxel cisplatin treat patient cervical cancer .</brief_summary>
	<brief_title>Radiation Therapy Plus Paclitaxel Cisplatin Treating Patients With Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity radiotherapy plus paclitaxel cisplatin use radiosensitization patient stage IB2 , IIA , IIB , IIIB , IVA invasive carcinoma cervix . - Determine maximum tolerate dose paclitaxel combine cisplatin plus radiotherapy patient . - Determine effect regimen maximum tolerated dose progression-free survival overall survival patient . - Determine site local distant recurrence patient treatment regimen . OUTLINE : This dose escalation study paclitaxel . Patients undergo external beam radiotherapy ( RT ) pelvic region 5 day week week 1-5 . Patients receive paclitaxel IV 1 hour immediately follow cisplatin concurrently pelvic field radiotherapy day 1 , 8 , 15 , 22 , 29 , 36 . Patients undergo low-dose rate ( LDR ) OR high-dose rate ( HDR ) brachytherapy . For patient undergo LDR brachytherapy , intracavitary implant insert 1 2 time within 3 week completion external beam RT . For patient undergo HDR brachytherapy , intracavitary implant insert week 5 week begin week 4 external beam RT . Patients may receive parametrial boost . Cohorts 3-6 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue treated MTD . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter time recurrence death . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 3-7 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IB2 , IIA , IIB , IIIB , IVA invasive carcinoma uterine cervix Any cell type No metastases paraaortic lymph node , scalene node , organ outside radiation field time original staging Study entry require within 8 week diagnosis PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : More 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Renal : Creatinine le 2.0 mg/dL No renal abnormality ( e.g. , pelvic kidney , horseshoe kidney , renal transplantation ) would require modification radiation field Other : Not pregnant No septicemia severe infection No invasive malignancy within past 3 year except nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy Chemotherapy : No prior chemotherapy prior malignancy Endocrine therapy : No prior endocrine therapy Radiotherapy : No prior pelvic abdominal radiotherapy malignancy No prior radiotherapy prior malignancy No 1 month interval surgery radiotherapy Surgery : See Radiotherapy Other : No prior therapy malignancy Stent nephrostomy tube required ureteral obstruction present</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical small cell carcinoma</keyword>
</DOC>